文献速递乳腺癌

来曲唑预防BRCA1/2突变绝经后女性乳腺癌的LIBER研究

Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study).
PubMed 文献 · Eur J Cancer · 2025-11-07

LIBER研究是一项随机双盲安慰剂对照III期试验,纳入170例携带胚系BRCA1/2突变的绝经后女性,随机接受5年来曲唑(2.5mg/天)或安慰剂。中位随访72.7个月后,5年浸润性乳腺癌发生率来曲唑组7.8%、安慰剂组13.1%,风险比0.70(95%CI 0.29-1.66),P=0.416,安全性及生活质量无统计学差异。研究因样本量不足未能证实显著获益,但趋势提示需更大样本进一步验证。

要点

  • 来曲唑组5年浸润性乳腺癌发生率7.8%,安慰剂组13.1%,HR 0.70(95%CI 0.29-1.66),未达统计学显著。
  • 治疗依从性来曲唑组76.7%,安慰剂组73.5%,安全性与生活质量两组无统计学差异。
  • 研究样本量不足,不能排除AI对BRCA1/2携带者整体或特定亚组的预防效果,需进一步随机对照试验。

核心结论

  • 由于试验把握度不足及观察到的趋势,不能排除使用芳香化酶抑制剂预防BRCA1/2携带者浸润性乳腺癌整体或特定亚组的有效性。
  • 需进一步随机对照试验确定AI对胚系BRCA1/2突变携带者的潜在获益。

研究设计与样本

  • LIBER为随机、双盲、安慰剂对照的III期试验。
  • 纳入40至70岁携带胚系BRCA1/2突变的绝经后女性,随机接受5年来曲唑(2.5 mg/天)或安慰剂。
  • 既往乳腺癌缓解超过5年者可入选以评估第二原发乳腺癌风险。
  • 随机按突变类型(BRCA1 vs BRCA2)、既往双侧卵巢切除术及既往乳腺癌分层。
  • 2008年至2013年共随机170例:安慰剂组86例,来曲唑组84例。

主要发现

  • 5年时治疗依从性安慰剂组73.5%,来曲唑组76.7%。
  • 中位随访72.7个月(95%CI 71.5-78.5),5年浸润性乳腺癌发生率安慰剂组13.1%,来曲唑组7.8%。
  • 风险比0.70(95%CI 0.29-1.66),P=0.416。
  • 安全事件与生活质量两组间无统计学差异。

关键数值与推荐

  • 主要终点为5年浸润性乳腺癌发生率。
  • 来曲唑剂量为2.5 mg/天,疗程5年。

临床怎么用

  • 目前证据尚不足以支持在BRCA1/2突变绝经后女性中常规使用来曲唑预防乳腺癌。
  • 临床决策需结合个体风险与获益,并告知患者研究未达主要终点且样本量有限。

局限性

  • 试验把握度不足。
  • 样本量较小(共170例)。
  • 需要更大样本的随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women carrying a germline BRCA1 or BRCA2 mutation (gBRCAm) have a 70 % lifetime risk of breast cancer (BC). Aromatase inhibitors (AI) decrease BC incidence in high-risk populations but have not been specifically assessed in gBRCAm carriers. METHODS: LIBER was a randomized, double-blind, placebo-controlled, phase III trial. Post-menopausal women aged between 40 and 70 years carrying a gBRCAm were randomly allocated either 5 years of letrozole (2.5 mg/day) or placebo. Women with prior BC in remission for more than 5 years ago were eligible to assess the risk of second BC. Randomization was stratified by type of gBRCAm (BRCA1 versus BRCA2), previous bilateral oophorectomy, and prior BC. The primary endpoint was the 5-year incidence of invasive BC. Safety and quality of life were analyzed. RESULTS: Between 2008 and 2013, 170 women were randomized: 86 to placebo and 84 to letrozole. At 5 years, treatment adherence was 73.5 % with placebo and 76.7 % with letrozole. After a median follow-up of 72.7 months (95 % CI 71.5-78.5), the 5-year incidence of invasive BC was 13.1 % with placebo and 7.8 % with letrozole: hazard ratio, 0.70 (95 % CI 0.29-1.66), p = 0.416. Safety events and quality of life did not statistically differ in the arm. CONCLUSION: Due to the underpowered nature of the trial and the observed trend, it cannot be ruled out that using AI to prevent invasive breast cancer could be effective for BRCA1/2 carriers overall, or for specific subgroups within a larger sample size. Further randomised controlled trials are needed to determine the potential benefits of AI for gBRCA1/2m carriers.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pujol P, Roca L, Lortholary A, et al. Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study). Eur J Cancer. 2025. PMID: 41240533. doi:10.1016/j.ejca.2025.116101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。